Senseonics Appoints Chief Financial Officer

Senseonics Holdings Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has appointed Jon D. Isaacson as chief financial officer (CFO), effective immediately. Concurrently, and as previously announced, R. Don Elsey has stepped down from the position and will continue in an advisory role to ensure an orderly transition and completion of the company’s annual U.S. Securities and Exchange Commission filings for the 2018 fiscal year.
 
“We are excited to welcome Jon to the Senseonics team. He brings a strong background of financial and operational success to the company at a pivotal time as we enter our next phase launching the Eversense system in the U.S.,” said Tim Goodnow, president and CEO. “His experience as an operator will be very valuable as we scale internally to support this launch. Again, we want to thank Don for his service and wish him well in the future.”
 
Isaacson has nearly 25 years of experience in financial leadership roles. Most recently he served as CFO of Edelman Financial Services, where he was responsible for financial planning and analysis, tax, treasury and corporate development. Under his leadership, the company completed a transformative merger and a successful financing. As a member of the executive team, he was involved in all facets of the business. Prior to this role, Isaacson was a managing director at a private equity firm, where he led the East Coast healthcare practice. There, he led approximately $1 billion of transactions and investments in companies within the healthcare sector, and subsequently assumed advisory and board of directors’ roles with several healthcare companies. Isaacson earned a masters degree in business administration from the Stanford Graduate School of Business and a bachelor of arts degree from the Johns Hopkins University.
 
Senseonics Holdings Inc. designs, develops, and commercializes glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense CGM System received PMA approval from the U.S. Food and Drug Administration for up to 90 days of continuous use and is available in the United States. The Eversense CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe.